Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
MWN-AI** Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB), a pioneer in live biotherapeutics, is set to present new research at the 2025 Digestive Disease Week (DDW) Conference from May 3-6 in San Diego, CA. The company will showcase three posters that build on previous findings from its SER-155 Phase 1b study, which supports its therapeutic mechanisms aimed at enhancing intestinal barrier integrity and modulating systemic inflammatory responses. These mechanisms are particularly relevant for treating inflammatory and immune diseases such as ulcerative colitis and Crohn’s disease.
One of the key presentations, titled "Characterization of IBD microbiomes in Models of Microbiome Disruption and Inflammation to Evaluate Candidate Biomarkers for Patient Selection," will be led by Principal Scientist Nicholas Beauchemin. This session aims to highlight potential biomarkers that can aid in the clinical development of live biotherapeutics. In addition, another presentation by Beauchemin will focus on identifying candidate biomarkers for patient stratification in clinical trials involving microbiome therapeutics for ulcerative colitis.
Moreover, Seres will offer an encore presentation by Senior Vice President of R&D, Christopher Ford, detailing pharmacokinetic and pharmacodynamic results from a randomized study on SER-155, which has shown promise in reducing bloodstream infection risks in adults undergoing allo-HSCT.
Seres Therapeutics is actively seeking partnerships to further advance its biotherapeutics, a strategy that follows its success in developing VOWST™, the first FDA-approved orally administered microbiome therapy. The company aims to target various vulnerable patient populations through its innovative live biotherapeutic programs.
Overall, the upcoming DDW Conference presents an excellent platform for Seres to share its latest research and developments in the burgeoning field of microbiome therapeutics.
MWN-AI** Analysis
Seres Therapeutics, Inc. (Nasdaq: MCRB) is poised to leverage its innovative pipeline of live biotherapeutics, especially following the positive presentation of data at the 2025 Digestive Disease Week (DDW) Conference. As a financial analyst, I believe this strategic move not only positions Seres favorably within the expanding realm of inflammatory and immune disease treatments but also opens the door for potential partnerships that could enhance its market reach and investment appeal.
The data from the SER-155 Phase 1b study demonstrates significant promise, showcasing the therapeutic capabilities of live biotherapeutics in conditions like ulcerative colitis and Crohn's disease. The focus on identifying candidate biomarkers is crucial, as it paves the way for improved patient selection and trial stratification, which could lead to more efficient clinical outcomes. This ongoing innovation aligns with the growing demand for targeted therapies in complex diseases, thus presenting a favorable market opportunity.
Investors should closely monitor Seres’ activities and potential collaborations that could catalyze accelerated development and commercialization of SER-155 and its other pipeline products, particularly in areas with high unmet medical needs such as allo-HSCT and chronic inflammatory diseases. The previously successful launch of VOWST™, the first FDA-approved oral microbiome therapeutic, illustrates Seres' capability to navigate regulatory challenges and successfully bring products to market, which enhances investor confidence.
Moreover, the healthcare sector's increasing shift towards personalized medicine and tailored approaches to disease treatment aligns well with Seres' business model. Given the strategic focus on cultivating novel therapies from standard clonal cell banks — improving scalability and consistency compared to traditional donor-derived methods — Seres embodies a resilient investment opportunity in an evolving biopharmaceutical landscape.
In conclusion, investors tracking Seres Therapeutics should adopt a bullish outlook, anticipating that the upcoming data presentations and potential partnerships could serve as catalysts for stock appreciation in the near future.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA.
Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases, including ulcerative colitis and Crohn’s disease.
Seres is currently seeking partnership opportunities to advance the development of its biotherapeutics in inflammatory and immune diseases.
Presentation Details - New Research
Title : Characterization of IBD microbiomes in Models of Microbiome Disruption and Inflammation to Evaluate Candidate Biomarkers for Patient Selection
Abstract Number : Sa1770
Presenter : Nicholas Beauchemin, Principal Scientist, R&D
Date & Time : May 3, 2025 from 12:30 PM to 1:30 PM
Title: Candidate Biomarkers of Microbiome Disruption for Patient Selection or Stratification in Clinical Trials of Microbiome Therapeutics in Ulcerative Colitis (UC)
Abstract Number: Sa1767
Presenter: Nicholas Beauchemin, Principal Scientist, R&D
Date & Time: May 3, 2025 from 12:30 PM to 1:30 PM
Presentation Details - Encore of Previously Disclosed Results
Title: Pharmacokinetic (PK) and pharmacodynamic (PD) results from a randomized, double-blind, placebo-controlled Cohort 2 of a Phase 1b study of an investigational, oral, live biotherapeutic, SER-155, in adults undergoing allo-HCT
Abstract Number: Su2009
Presenter: Christopher Ford, SVP, R&D
Date & Time: May 4, 2025 from 12:30 PM to 1:30 PM
Digestive Disease Week ® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases nearly 6,000 abstracts and over 1,000 invited talks on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org .
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com .
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ**
What insights have emerged from the SER-155 Phase study regarding its potential efficacy in reducing bloodstream infections, and how could "Seres Therapeutics Inc. MCRB" leverage this data to attract partnerships for further development?
How might the candidate biomarkers identified at the DDW Conference enhance the clinical trial design for "Seres Therapeutics Inc. MCRB," particularly in selecting and stratifying patients with ulcerative colitis and Crohn's disease?
Given the successful approval of VOWST™, what strategies is "Seres Therapeutics Inc. MCRB" planning to implement to capitalize on this achievement while advancing SER-155 and other pipeline programs in the live biotherapeutics space?
How does "Seres Therapeutics Inc. MCRB" plan to use its Breakthrough Therapy designation for SER-155 to expedite clinical development and address unmet needs within the medically vulnerable populations it aims to serve?
**MWN-AI FAQ is based on asking OpenAI questions about Seres Therapeutics Inc. (NASDAQ: MCRB).
NASDAQ: MCRB
MCRB Trading
-0.46% G/L:
$8.69 Last:
19,989 Volume:
$9 Open:
